What are the definition, diagnostic criteria, recommended investigations, and management for multibacillary leprosy?

Multibacillary Leprosy: Comprehensive Overview

Definition

Multibacillary (MB) leprosy represents the lepromatous end of the leprosy spectrum, characterized by high bacterial loads of Mycobacterium leprae, defective cell-mediated immunity, and the presence of numerous acid-fast bacilli in tissues 1, 2. This form harbors large numbers of bacteria with high levels of anti-M. leprae antibodies that are seemingly non-protective 1.

The clinical spectrum of leprosy directly parallels host immunity:

• Paucibacillary (PB) leprosy: Vigorous pro-inflammatory immunity with few bacteria
• Multibacillary (MB) leprosy: Weak cell-mediated immunity with extensive bacterial proliferation

Diagnosis

Clinical Classification Criteria

The WHO classification system uses skin lesion count for treatment purposes, though this method has significant limitations 3:

WHO Classification (for treatment):

• Multibacillary: >5 skin lesions
• Paucibacillary: ≤5 skin lesions

Critical caveat: Studies show that 38-51% of patients classified as paucibacillary by skin lesion count actually have multibacillary disease by classic microbiological criteria, risking undertreatment 3.

Cardinal Diagnostic Features

The three cardinal criteria remain the diagnostic gold standard 4:

1. Anaesthetic skin patches (hypopigmented or erythematous)
2. Thickened peripheral nerves (palpable on examination)
3. Acid-fast bacilli in skin slit smears

Clinical Presentations of Multibacillary Disease

Lepromatous leprosy (LL) typically presents with:

• Multiple erythematous papules and nodules 5
• Bilateral and symmetrical skin infiltration 6
• Diffuse facial, hand, and foot thickening
• Ichthyosiform scaling (often misdiagnosed) 7
• Hypopigmented macules
• Bilateral peripheral neuropathy in stocking-glove distribution 7
• Palpably thickened ulnar, median, and peroneal nerves

Autonomic dysfunction may indicate advanced disease 7, manifesting as orthostatic hypotension and anhidrosis.

Investigations

Essential Diagnostic Tests

1. Skin Slit Smear (Bacteriological Index - BI)

• Gold standard for bacterial load assessment 2
• Multibacillary: BI typically 3+ to 6+
• Samples taken from earlobes, elbows, and active lesions
• Limitation: Requires technical expertise, not widely available

2. Skin Biopsy

• Histopathology shows: Diffuse histiocytic infiltrate with foamy macrophages (Virchow cells) containing numerous acid-fast bacilli 7
• More reliable than skin lesion count for true classification 3

3. Serological Testing

• Anti-PGL-1 antibodies correlate with bacterial load 8
• Useful adjunct for classification when bacteriological examination unavailable
• Presence of antibodies to M. leprae-specific antigens correlates with multibacillary disease 8

4. Molecular Testing

• Quantitative RT-PCR for molecular viability assessment 9
• Can detect M. leprae DNA and assess treatment response
• Not routinely available but increasingly important for monitoring

Baseline Monitoring Before Treatment

Before initiating multidrug therapy, obtain:

• Complete blood count (baseline for dapsone-related hemolysis)
• Liver function tests (baseline for rifampin monitoring)
• Renal function tests
• G6PD testing (dapsone causes hemolysis in G6PD deficiency) 10
• Ophthalmologic examination if clofazimine used (conjunctival pigmentation risk) 11
• ECG if clofazimine used (QTc prolongation risk) 12, 11
• Nerve function assessment and documentation

Management

Standard Multidrug Therapy (MDT)

The WHO-recommended multidrug therapy for multibacillary leprosy consists of a 12-month regimen 1, 2:

Adult Dosing:

• Rifampin: 600 mg once monthly (supervised)
• Dapsone: 100 mg daily (self-administered)
• Clofazimine: 300 mg once monthly (supervised) + 50 mg daily (self-administered)

Pediatric Dosing:

• Rifampin: 10-15 mg/kg once monthly
• Dapsone: 1-2 mg/kg daily (maximum 100 mg)
• Clofazimine: 3-5 mg/kg/day (maximum 100 mg/day) 12

Treatment Duration Considerations

Standard duration is 12 months for multibacillary leprosy 1, 2, though:

• Some experts advocate longer treatment for high bacterial loads (BI >4+)
• Optimal duration remains debated 4
• Treatment should continue until clinical improvement and bacterial clearance documented

Clofazimine-Specific Monitoring

Clofazimine requires specific counseling and monitoring 11:

Adverse Effects:

• Skin discoloration (pink to brownish-black) occurs in 75-100% of patients within 1-4 weeks 11
• Critical counseling point: Discoloration usually resolves 6-12 months after stopping treatment
• Ichthyosis and dry skin (8-38%)
• Gastrointestinal symptoms (up to 50%): Take with meals to minimize

Monitoring Requirements:

• ECG: Baseline, at 2 weeks, and after adding any QT-prolonging medication 11
• Monthly ECG if multiple QTc-prolonging agents used 12
• Monitor for conjunctival pigmentation and visual symptoms 11

Management of Leprosy Reactions

Type 2 Reaction (Erythema Nodosum Leprosum - ENL):

ENL can occur during or after treatment 5, presenting with:

• Painful erythematous nodules
• Fever and systemic symptoms
• Neuritis

Treatment approach:

• Continue MDT without interruption 5
• Thalidomide: First-line for ENL (100-400 mg/day)
• Corticosteroids: Alternative if thalidomide contraindicated
• Critical: Thalidomide absolutely contraindicated in pregnancy (teratogenic)

Emerging Therapies

Bedaquiline shows promising results 9:

• 8-week bedaquiline monotherapy cleared M. leprae by 4 weeks in a proof-of-concept study
• Improved skin lesions by 7 weeks
• Well-tolerated (all adverse events grade 1-2)
• Not yet standard of care but represents potential future alternative for patients with severe MDT side effects

Treatment Monitoring

During treatment, monitor:

• Monthly clinical assessment: Skin lesion improvement, new lesions, nerve function
• Routine toxicity monitoring (CBC, LFTs, renal function) at 3,6,9, and 12 months 11
• Slit smear at 6 and 12 months to document bacterial clearance
• Nerve function testing every 3 months to detect silent neuritis

Common Pitfalls to Avoid

1. Misclassification by skin lesion count alone: Always correlate with bacteriological findings when possible 3
2. Stopping MDT during reactions: Continue antimicrobial therapy while treating reactions 5
3. Inadequate patient counseling about clofazimine pigmentation: This causes significant psychological distress and treatment discontinuation 11
4. Missing autonomic dysfunction: Indicates advanced disease requiring aggressive management 7
5. Overlooking concurrent tuberculosis: Lepromatous leprosy predisposes to TB reactivation 7

Special Considerations

In patients with concurrent conditions:

• HIV co-infection: Higher risk of false-positive serological tests 13; maintain standard MDT duration
• Pregnancy: Avoid thalidomide; continue MDT with close monitoring
• Liver disease: Monitor LFTs more frequently; rifampin dose adjustment may be needed
• Renal impairment: Adjust dapsone dosing

Post-Treatment Follow-Up

After completing 12-month MDT:

• Clinical examination every 6 months for 5 years
• Monitor for relapse (new skin lesions, increased BI)
• Relapse rates are low with proper MDT (typically <1% at 5 years) 4
• Assess for late nerve damage and disability prevention